Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00235794 · ClinicalTrials.gov registry record · NA
An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients
A NA study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT00235794 is a NA study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 50 participants.
The verdict
NCT00235794, a NA study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
Open-label exloratory pharmacodynamic and pharmacogenomic study to evaluate teh biologic effects of 3 dose levels (1mg, 5 mg, and 15 mg) of temsirolimus administered orally once daily for approximately 4 weeks (+/- 2 weeks) before prostatectomy
Interventions
- DRUG temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2004-01 |
| Est. Completion | 2007-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00235794
The ClinicalTrials.gov registry entry for NCT00235794 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which temsirolimus is the first listed.
NCT00235794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00235794 about?
NCT00235794 is a clinical study titled "An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients". Open-label exloratory pharmacodynamic and pharmacogenomic study to evaluate teh biologic effects of 3 dose levels (1mg, 5 mg, and 15 mg) of temsirolimus administered orally once daily for approximately 4 weeks (+/- 2 weeks) before prostatectomy
What is the current status of trial NCT00235794?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2004-01. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00235794?
The interventions under investigation include: temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00235794?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.